It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Discover precise insights into brain neurochemistry with Sygnature Discovery's in vivo microdialysis and cOFM services. With over 20 years of expertise, we design bespoke studies that reveal how compounds modulate neurotransmitter systems in health and disease. Using UHPLC/HPLC with electrochemical detection or mass spectrometry, we deliver robust PK/PD data to support confident CNS decision making.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesized and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesized and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Explore careers at Sygnature Discovery and join a global team committed to science, collaboration, and integrity.
Target Classes
Driving discovery across diverse target classes with integrated expertise and advanced, decision-ready solutions.
From ion channels and GPCRs to transporters, kinases, helicases, and more, co-located teams deliver tailored workflows and collaborate to accelerate your program from target validation to candidate selection.
Novel therapies begin with understanding the molecular mechanisms that drive disease. That’s why we start with the biology of the target.
Deep target and therapeutic area expertise helps us identify the questions that matter, then bring together the right capabilities and strategies to answer them. By putting target understanding first, we generate meaningful evidence earlier, helping reduce downstream risk and progress promising therapies.
Target class drug discovery expertise
Our target-class specialists combine deep biological and pharmacological knowledge with extensive assay development, screening and drug discovery experience.
Whether you need specialist support for a defined challenge or expertise embedded within an integrated program, we can build the experimental strategy around your target, existing evidence and program objectives.
Ion Channels
Comprehensive ion channel screening and electrophysiology capabilities
Our ion channel capabilities span assay development, screening and compound profiling across a broad range of therapeutically relevant channels.
With more than 150 validated recombinant cell lines, fluorescence-based assays and advanced electrophysiology platforms, we generate functional and mechanistic data to support compound progression.
Deep GPCR pharmacology, assay development and screening expertise
Access extensive GPCR pharmacology and cell-signaling expertise, supported by bespoke assay development, transient and stable cell lines, and high-throughput screening capabilities.
We develop functional assays and screening cascades across diverse receptor mechanisms and signaling pathways to characterize compound activity, interrogate mechanism and generate robust data for progression.
Bespoke transporter assays, screening and compound characterization
Our transporter expertise combines deep understanding of transporter biology and pharmacology with bespoke cell-based assays, electrophysiology and screening capabilities.
Tailored assay and screening cascades enable us to characterize compound activity, investigate transporter function and build confidence in mechanism and selectivity across diverse transporter families.
Deep target understanding. Better discovery decisions.
A compelling target association is a starting point, not a discovery strategy.
Understanding target function in the context of disease biology can influence whether and how a target should be pursued, from the required mechanism of modulation to assay design, compound profiling and translational strategy.
Target class expertise adds another critical layer. Each target class bring distinct pharmacological opportunities, liabilities and technical challenges that need to be considered as a program progresses.
Our teams combine this understanding with practical discovery experience to design experiments around the decisions your program needs to make.
Support tailored to your program
Specialist expertise where you need it, integrated discovery when you need it
Every program comes to us at a different point.
You may need a bespoke assay for a challenging target, specialist pharmacology to characterize compounds, additional screening capacity or support resolving a specific mechanistic question.
Or you may be looking for an integrated team capable of progressing a program across multiple stages of discovery.
Our target class scientists work as an extension of your existing team, bringing in expertise across bioscience, structural biology, computational science, medicinal chemistry, DMPK and in vivo pharmacology as required.
Understanding target biology is critical to making informed decisions throughout drug discovery. By combining pathway analysis, omics data, and target-class expertise, researchers can build a clearer picture of disease mechanisms, identify the most effective intervention strategies, and reduce scientific risk before significant resources are committed.
Drug Discovery research heavily relies on cell-based assay systems to investigate cellular functions and…
eBooks
FAQs
Yes. Our scientists develop custom assays tailored to target mechanism, biological context and program objectives. Assay development can support a defined study or form part of a wider screening and discovery cascade.
Yes. We can work with established assays and existing program data, including assay transfer and optimization where appropriate.
Yes. We can develop bespoke experimental strategies for emerging and technically challenging targets where established assays or screening approaches may not be appropriate. The approach is determined by the target biology, mechanism and evidence required to progress the program.
An error has occurred, please try again later.An error has occurred, please try again later.
You're in the right place!
Peak Proteins, NuChem Sciences, and SB Drug Discovery have now fully integrated with Sygnature Discovery.
